KRAS testing for anti-EGFR therapy in advanced colorectal cancer : an evidence-based and economic analysis
Medical Advisory Secretariat
Record ID 32011000419
English
Authors' objectives:
The objective of this systematic review is to determine the predictive value of KRAS testing in the treatment of metastatic colorectal cancer (mCRC) with two anti-EGFR agents, cetuximab and panitumumab. Economic analyses are also being conducted to evaluate the cost-effectiveness of KRAS testing.
Authors' recommendations:
KRAS status is predictive of outcomes in cetuximab and panitumumab monotherapy, and in cetuximab-irinotecan combination therapy.While KRAS testing is cost-effective for all strategies considered, it is not equally cost-effective for all treatment options.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.health.gov.on.ca/english/providers/program/mas/tech/reviews/pdf/KRAS_20101213.pdf
URL for additional information:
http://www.hqontario.ca/en/mas/mas_ohtas_tech_kras_20101213.html
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Colorectal Neoplasms
- Costs and Cost Analysis
- Mutation
- Predictive Value of Tests
- Cetuximab
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
Contact
Organisation Name:
Medical Advisory Secretariat
Contact Address:
Medical Advisory Secretariat, 20 Dundas Street West, 10th Floor, Toronto, ON M5G 2N6 CANADA. Tel: 416-314-1092l; Fax: 416-325-2364;
Contact Name:
MASinfo.moh@ontario.ca
Contact Email:
MASinfo.moh@ontario.ca
Copyright:
<p>Medical Advisory Secretariat, Ontario Ministry of Health and Long-Term Care</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.